Obagi Medical has announced significant clinical findings regarding its hyaluronic acid injectables during the American Society for Dermatologic Surgery (ASDS) Annual Meeting held from November 13 to 16, 2025, in Chicago, Illinois. The new data highlights the effectiveness of Obagi’s hyaluronic acid fillers in midface augmentation and improving the appearance of nasolabial folds. These findings were presented by Dr. Sue Ellen Cox and have earned recognition as one of the top ten abstracts at the event.
The pivotal study, which involved a comparison of two hyaluronic acid fillers, demonstrated substantial improvements in patient outcomes. Obagi’s injectables were shown to enhance midfacial volume while effectively reducing the visibility of nasolabial folds, a common concern for individuals seeking aesthetic treatments. This clinical data not only underscores the efficacy of Obagi’s products but also reflects the company’s commitment to advancing skincare solutions.
According to the research presented, patients receiving Obagi’s hyaluronic acid injectables reported high satisfaction rates regarding the aesthetic results. The study’s findings suggest that these injectables not only address immediate cosmetic concerns but also contribute to long-term skin health and appearance.
The ASDS Annual Meeting, a key gathering for dermatology professionals, offered a platform for sharing cutting-edge research and clinical advancements. Obagi Medical, a division of Waldencast plc (NASDAQ: WALD), has positioned itself as a leader in physician-dispensed skincare products. The recognition from the ASDS highlights the innovative nature of Obagi’s offerings, further solidifying its role in the aesthetic medicine landscape.
As the demand for effective and safe aesthetic solutions continues to grow, Obagi Medical’s latest findings may influence treatment protocols and patient choices within the dermatological community. The company’s focus on evidence-based products aligns with the broader trend of personalized skincare, emphasizing the importance of clinical validation in aesthetic procedures.
In conclusion, the results shared at the ASDS Annual Meeting mark a significant milestone for Obagi Medical, showcasing its dedication to improving patient outcomes through research and innovation. The recognition of Dr. Sue Ellen Cox’s presentation not only highlights the quality of the data but also positions Obagi as a front-runner in the competitive field of aesthetic medicine.
